Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 2/20 | 0.49 |
| ▸ | LPL | P06858 | 12/20 | 0.42 |
| ▸ | LIPG | Q9Y5X9 | 12/20 | 0.42 |
| ▸ | F11 | P03951 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | CA9 | Q16790 | 2/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA3 | P07451 | 1/20 | 0.36 |
| ▸ | CA4 | P22748 | 1/20 | 0.36 |
| ▸ | CA6 | P23280 | 1/20 | 0.36 |
| ▸ | CA5A | P35218 | 1/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.36 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19329278 | 0.94 | DGAT1 (0.48) | DGAT1LPLLIPGF11CA1 | |
| SCHEMBL2585735 | 0.86 | DGAT1 (0.46) | DGAT1LPLLIPGF11CA1 | |
| SCHEMBL2486269 | 0.86 | DGAT1 (0.46) | DGAT1LPLLIPGF11CA1 | |
| SCHEMBL6937341 | 0.84 | DGAT1 (0.44) | DGAT1LPLLIPGF11CA1 | |
| SCHEMBL29520942 | 0.84 | DGAT1 (0.47) | DGAT1LPLLIPGF11CA1 | |
| SCHEMBL16554154 | 0.84 | DGAT1 (0.47) | DGAT1LPLLIPGF11CA1 | |
| SCHEMBL2426973 | 0.83 | LPL (0.49) | DGAT1LPLLIPGF11CA1 | |
| SCHEMBL29744209 | 0.83 | LPL (0.49) | DGAT1LPLLIPGF11CA1 | |
| SCHEMBL31469579 | 0.82 | LPL (0.45) | DGAT1LPLLIPGF11CA1 | |
| SCHEMBL2428561 | 0.82 | LPL (0.45) | DGAT1LPLLIPGF11CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026099455-A1 | DIHYDROPYRROLOPYRIMIDINONE COMPOUNDS AS TREM2 MODULATORS | MUNA THERAPEUTICS APS (DK) | 2026-05-15 | — | — | WO | disclosed |
| US-20240165121-A1 | SUBSTITUTED BENZENE COMPOUNDS | EPIZYME INC (US) | 2024-05-23 | — | — | US | disclosed |
| US-11642348-B2 | Substituted benzene compounds | Epizyme, Inc. (US) | 2023-05-09 | — | — | US | disclosed |
| US-11642348-B2 | Substituted benzene compounds | Epizyme, Inc. (US) | 2023-05-09 | — | — | US | disclosed |
| US-11642348-B2 | Substituted benzene compounds | Epizyme, Inc. (US) | 2023-05-09 | — | — | US | disclosed |
| US-20210060027-A1 | SUBSTITUTED BENZENE COMPOUNDS | Epizyme, Inc. | 2021-03-04 | — | — | US | disclosed |
| US-20210060027-A1 | SUBSTITUTED BENZENE COMPOUNDS | Epizyme, Inc. | 2021-03-04 | — | — | US | disclosed |
| EP-3725314-A1 | SUBSTITUTED BENZENE COMPOUNDS | Epizyme, Inc. (US) | 2020-10-21 | — | — | EP | disclosed |
| EP-3725314-A1 | SUBSTITUTED BENZENE COMPOUNDS | Epizyme, Inc. (US) | 2020-10-21 | — | — | EP | disclosed |
| US-10676479-B2 | Imidazolepyridine compounds and uses thereof | NOVARTIS AG (CH) | 2020-06-09 | — | — | US | disclosed |
| WO-2017162611-A1 | QUINOLINE-3-CARBOXAMIDE COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2017-09-28 | — | — | WO | disclosed |
| WO-2017153578-A1 | IMIDAZO[4,5-C]QUINOLIN-2-ONE COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2017-09-14 | — | — | WO | disclosed |
| WO-2017153578-A1 | IMIDAZO[4,5-C]QUINOLIN-2-ONE COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2017-09-14 | — | — | WO | disclosed |
| US-20150284370-A1 | SUBSTITUTED BENZENE COMPOUNDS | Epizyme, Inc. | 2015-10-08 | — | — | US | disclosed |
| US-20150284370-A1 | SUBSTITUTED BENZENE COMPOUNDS | Epizyme, Inc. | 2015-10-08 | — | — | US | disclosed |
| US-20150284370-A1 | SUBSTITUTED BENZENE COMPOUNDS | Epizyme, Inc. | 2015-10-08 | — | — | US | disclosed |
| EP-2906537-A2 | SUBSTITUTED BENZENE COMPOUNDS | Epizyme, Inc. (US) | 2015-08-19 | — | — | EP | disclosed |
| WO-2014062733-A2 | SUBSTITUTED BENZENE COMPOUNDS | Epizyme, Inc. (US) | 2014-04-24 | — | — | WO | disclosed |
| WO-2014062733-A2 | SUBSTITUTED BENZENE COMPOUNDS | Epizyme, Inc. (US) | 2014-04-24 | — | — | WO | disclosed |
| WO-2013053273-A1 | IMIDAZO QUINOLINE DERIVATIVE AND MEDICINAL SALT THEREOF, PREPARATION METHOD THEREOF AND USE IN MEDICINE THEREOF | 上海恒瑞医药有限公司 (CN) | 2013-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150284370-A1 | SUBSTITUTED BENZENE COMPOUNDS | CYP1B1, TP53, VHL | DGAT1 3770/4885LPL 4110/4885LIPG 4167/4885 |
| US-10676479-B2 | Imidazolepyridine compounds and uses thereof | EZH2, DOT1L, BMI1 | DGAT1 4729/4885LPL 4799/4885LIPG 4805/4885 |
| US-20210060027-A1 | SUBSTITUTED BENZENE COMPOUNDS | CYP1B1, TP53, VHL | DGAT1 3770/4885LPL 4110/4885LIPG 4167/4885 |
| US-20240165121-A1 | SUBSTITUTED BENZENE COMPOUNDS | CYP1B1, TP53, VHL | DGAT1 3770/4885LPL 4110/4885LIPG 4167/4885 |
| US-11642348-B2 | Substituted benzene compounds | CYP1B1, TP53, VHL | DGAT1 3770/4885LPL 4110/4885LIPG 4167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.